Antibody-Drug Conjugate– tag –
-
Lonza Significantly Expands Biologics Manufacturing Capacity by Over 200,000 Liters with New Swiss Facility
Lonza Press Release Switzerland Overview Lonza announced the operational launch of a state-of-the-art new facility in Visp, Switzerland, significantly expanding its biopharmaceutical manufacturing capabilities. This expansion adds over 2... -
Daiichi Sankyo and AstraZeneca’s Gastric Cancer ADC Receives Positive EMA CHMP Opinion for Approval
European Medicines Agency (EMA) Europe Overview The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, recommending approval for an antibody-drug conjugate (ADC) develo... -
WuXi Biologics Intensifies Focus on South Korea to Bolster K-Biotech Partnerships Amid US Pressure
BioCentury (Chosun Biz) South Korea Overview WuXi Biologics is expanding its sales efforts in South Korea, actively targeting K-biotech companies amidst increasing U.S. legislative scrutiny on Chinese biotech firms. As a major global Con... -
WuXi Biologics Shanghai Drug Product Facility Achieves GMP Release, Expands Global Capacity
Contract Pharma China Overview WuXi Biologics' Drug Product Facility 15 (DP15) in Shanghai secured Good Manufacturing Practice (GMP) release in April 2026, becoming its 18th operational drug product facility globally. This state-of-the-a... -
Daiichi Sankyo Unveils Extensive Oncology Portfolio Progress at ASCO; Datopotamab Deruxtecan Approved for First-Line mTNBC
Daiichi Sankyo (Press Release), MedCity News, ADC Review, FirstWord Pharma Japan Overview Daiichi Sankyo will present over 25 abstracts at the 2026 ASCO Annual Meeting, showcasing its leading oncology portfolio, including new clinical da... -
WuXi Biologics Hosts Third CRDMO Day in Tokyo, Accelerating Japanese Biopharma Innovation
PR Newswire Japan Overview WuXi Biologics successfully hosted its third CRDMO Day in Tokyo, gathering key leaders and experts from Japan's biopharmaceutical sector to discuss market trends and best practices in biologics innovation. The ... -
Henlius Gains NMPA IND Approval for HLX48, a Bispecific c-Met/EGFR Antibody-Drug Conjugate for Solid Tumors
FirstWord Pharma China Overview Shanghai Henlius Biotech, Inc. announced that its self-developed c-Met/EGFR bispecific antibody-drug conjugate (ADC), HLX48, has received Investigational New Drug (IND) approval from China's National Medic... -
NEOK002: Next-Generation Bispecific ADC Targeting EGFR and MUC1 Enters Clinical Development for Solid Tumors
Conference Coverage AACR USA Overview NEOK002 (formerly ABL209), a bispecific antibody-drug conjugate (ADC), has entered clinical development, designed to concurrently target two key cancer antigens, EGFR and MUC1, implicated in epitheli... -
Thousand Oaks Biologics Honored with Forbes China Industry Award for Leading ADC CDMO Capabilities
TMX Newsfile China Overview Thousand Oaks Biologics has been awarded the "2026 Forbes China Industry Development Leading Enterprise Award" for its advanced capabilities in antibody-drug conjugate (ADC) manufacturing. Operating across Chi... -
Daiichi Sankyo Records Significant Loss Due to ADC Supply ‘Miscalculation’ Despite Strong Enhertu Sales, Raising Risk Management Questions
東洋経済オンライン Japan Overview Japanese pharmaceutical giant Daiichi Sankyo reported a substantial operating profit decrease for FY2025 despite record sales, attributing a 169.5 billion yen loss provision to compensation for Antibody-...
